Ex-Dividend Alert: West Pharmaceutical Services, Cohen & Steers Tax-Advantaged Preferred Securities, and Home BancShares
Upcoming Ex-Dividend Dates: On 11/12/25, West Pharmaceutical Services (WST), Cohen & Steers Tax-advantaged Preferred Securities (PTA), and Home BancShares Inc (HOMB) will trade ex-dividend, with respective dividends of $0.22, $0.134, and $0.21 scheduled for payment on 11/19/25, 11/28/25, and 12/3/25.
Expected Price Adjustments: Following the ex-dividend dates, WST shares are expected to open 0.08% lower, PTA by 0.67%, and HOMB by 0.76%, based on their recent stock prices.
Dividend Yield Estimates: The estimated annualized yields for the upcoming dividends are 0.32% for WST, 8.09% for PTA, and 3.06% for HOMB, indicating varying levels of return for investors.
Market Performance: In recent trading, WST shares are down about 1.6%, while PTA shares have increased by 0.1% and HOMB shares are up by 1.4%.
Trade with 70% Backtested Accuracy
Analyst Views on WST
About WST
About the author
WEST PHARMACEUTICAL SERVICES INC: UBS LOWERS TARGET PRICE FROM $355 TO $340
Company Overview: West Pharmaceutical Services, Inc. is a leading provider of pharmaceutical packaging and delivery solutions.
Stock Price Adjustment: The company has cut its target stock price from $355 to $340.
West Pharmaceutical Services Reports Strong Q4 2025 Earnings and Positive Outlook
- Significant Revenue Growth: West Pharmaceutical achieved $805 million in revenue for Q4 2025, reflecting a 7.5% increase year-over-year, with organic growth at 3.3%, indicating strong demand and enhanced market position in the biopharmaceutical sector.
- Improved Profitability: The adjusted earnings per share (EPS) reached $2.04, up 12% from the previous year, while gross margin stood at 37.8%, a 130 basis point increase, showcasing the company's success in cost control and product value enhancement.
- Optimistic Future Outlook: Management guided for 2026 revenue between $3.215 billion and $3.275 billion, with organic growth projected at 5% to 7%, emphasizing that HVP components will be the primary growth driver, reflecting confidence in future market conditions.
- Strong Cash Flow: Free cash flow for 2025 reached $469 million, a 70% year-over-year increase, providing a solid foundation for future investments and shareholder returns, indicating robust financial health.
West Pharma (WST) Q4 2025 Earnings Call Transcript
WEST PHARMACEUTICAL SERVICES STOCK RISES 2.8% FOLLOWING POSITIVE 2026 PROFIT OUTLOOK
Stock Performance: West Pharmaceutical Services shares increased by 2.8%.
Profit Forecast: The company provided an upbeat profit forecast for 2026.
West Pharma Executive Reports Steady Customer Behavior and Calls Annual Forecast a Conservative Beginning - Conference Call
Customer Behavior Insights: West Pharma executives report no significant changes in customer behavior, indicating stability in their market interactions.
Annual Forecast Overview: The company describes its annual forecast as conservative, reflecting a cautious approach to future business expectations.
West Pharma Executive Anticipates GLP-1 Demand Growth in 2026, but Slower than 2025 - Conference Call Insights
- Growth Expectations: West Pharma executives anticipate that demand for GLP-1 medications will grow in 2026, albeit at a slower pace than in 2025.
- Market Trends: The company is observing trends in the pharmaceutical market that may influence the production and demand for these medications.
WEST PHARMACEUTICAL SERVICES INC: UBS LOWERS TARGET PRICE FROM $355 TO $340
Company Overview: West Pharmaceutical Services, Inc. is a leading provider of pharmaceutical packaging and delivery solutions.
Stock Price Adjustment: The company has cut its target stock price from $355 to $340.
West Pharmaceutical Services Reports Strong Q4 2025 Earnings and Positive Outlook
- Significant Revenue Growth: West Pharmaceutical achieved $805 million in revenue for Q4 2025, reflecting a 7.5% increase year-over-year, with organic growth at 3.3%, indicating strong demand and enhanced market position in the biopharmaceutical sector.
- Improved Profitability: The adjusted earnings per share (EPS) reached $2.04, up 12% from the previous year, while gross margin stood at 37.8%, a 130 basis point increase, showcasing the company's success in cost control and product value enhancement.
- Optimistic Future Outlook: Management guided for 2026 revenue between $3.215 billion and $3.275 billion, with organic growth projected at 5% to 7%, emphasizing that HVP components will be the primary growth driver, reflecting confidence in future market conditions.
- Strong Cash Flow: Free cash flow for 2025 reached $469 million, a 70% year-over-year increase, providing a solid foundation for future investments and shareholder returns, indicating robust financial health.
West Pharma (WST) Q4 2025 Earnings Call Transcript
WEST PHARMACEUTICAL SERVICES STOCK RISES 2.8% FOLLOWING POSITIVE 2026 PROFIT OUTLOOK
Stock Performance: West Pharmaceutical Services shares increased by 2.8%.
Profit Forecast: The company provided an upbeat profit forecast for 2026.
West Pharma Executive Reports Steady Customer Behavior and Calls Annual Forecast a Conservative Beginning - Conference Call
Customer Behavior Insights: West Pharma executives report no significant changes in customer behavior, indicating stability in their market interactions.
Annual Forecast Overview: The company describes its annual forecast as conservative, reflecting a cautious approach to future business expectations.
West Pharma Executive Anticipates GLP-1 Demand Growth in 2026, but Slower than 2025 - Conference Call Insights
- Growth Expectations: West Pharma executives anticipate that demand for GLP-1 medications will grow in 2026, albeit at a slower pace than in 2025.
- Market Trends: The company is observing trends in the pharmaceutical market that may influence the production and demand for these medications.
